TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31519516

Group type: EXPERIMENTAL
Intervention: Transrectal in-bore MRI targeted biopsy (MRI-TB)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Transperineal MRI-transrectal ultrasound fusion targeted biopsy (FUS-TB)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Transrectal cognitive TRUS targeted biopsy (COG-TB)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Transrectal approaches (MRI-TB + COG-TB)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Biopsy
Number of subjects: 234
Study: 28376972

Group type: EXPERIMENTAL
Intervention: Adult-led workshop
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Peer-led workshop
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 32
Study: 25953805

Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) for piperacillin, adjusted to achieve 100% fT>MIC
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) for piperacillin, adjusted to achieve 50% fT>MIC
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) for piperacillin, baseline to after third TDM
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no TDM)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Duration of fever and days to recovery from neutropenia
Number of subjects: 32
Study: 22986930

Group type: EXPERIMENTAL
Intervention: High-dose retinol supplement (25,000 IU retinyl palmitate/day) for up to 16 years
Number of subjects: 2322

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation
Number of subjects: 2322
Study: 21839850

Group type: EXPERIMENTAL
Intervention: Olodaterol 2 μg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Olodaterol 5 μg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Olodaterol 10 μg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Olodaterol 20 μg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Olodaterol (all doses)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Olodaterol (40 μg)
Number of subjects: 36
Study: 18068876

Group type: EXPERIMENTAL
Intervention: Candidate vaccine (recombinant protein HIV-1 gp160MN/LAI with or without DC-Chol adjuvant) administered by the nasal or vaginal route
Number of subjects: 34
Study: 16858354

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day
Number of subjects: 70

Group type: COMPARATOR
Intervention: No statin (control)
Number of subjects: 70
Study: 15199384

Group type: EXPERIMENTAL
Intervention: Plant sterol ester-enriched (PSE) spread (20 g/day)
Number of subjects: 57
Study: 11270916

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/day (increased to 40 mg/day after 2 weeks)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Amitriptyline 75 mg/day (increased to 150 mg/day after 2 weeks)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combined lithium and antidepressant therapy (both paroxetine and amitriptyline)
Number of subjects: 31
Study: 9416712

Group type: EXPERIMENTAL
Intervention: Preschool-sevoflurane
Number of subjects: 63

Group type: COMPARATOR
Intervention: Preschool-halothane
Number of subjects: 63

Group type: COMPARATOR
Intervention: School-sevoflurane
Number of subjects: 63

Group type: COMPARATOR
Intervention: School-halothane
Number of subjects: 63
Study: 8119050

Group type: EXPERIMENTAL
Intervention: Theophylline concentration of 10 mg/L
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Theophylline concentration of 20 mg/L
Number of subjects: 174

Group type: COMPARATOR
Intervention: No theophylline
Number of subjects: 174
Study: 3687315

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (Trental 400)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional antihypertensive therapy
Number of subjects: 21
Study: 29363365

Group type: EXPERIMENTAL
Intervention: EV71 vaccine
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1400
Study: 27461547

Group type: EXPERIMENTAL
Intervention: 14mg nicotine patch
Number of subjects: 52

Group type: COMPARATOR
Intervention: placebo patch
Number of subjects: 52
Study: 24892144

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Nedocromil
Number of subjects: 1041

Group type: COMPARATOR
Intervention: Oral prednisone
Number of subjects: 1041

Group type: COMPARATOR
Intervention: Additional controller medications
Number of subjects: 1041

Group type: COMPARATOR
Intervention: Pulmonary function
Number of subjects: 1041
Study: 23761646

Group type: EXPERIMENTAL
Intervention: Diet rich in n3 PUFAs (3.5% of energy intake)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control diet (0.5% of energy intake from n3 PUFAs)
Number of subjects: 24
Study: 20639852

Group type: EXPERIMENTAL
Intervention: LY2140023
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18724650

Group type: EXPERIMENTAL
Intervention: Tretinoin 0.04% microsphere gel (TMG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adapalene 0.3% gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tretinoin 0.025% cream
Number of subjects: 0
Study: 15917019

Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation for 6 months
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 14584976

Group type: EXPERIMENTAL
Intervention: Objects categorized and located in the same quadrant of the box
Number of subjects: 0

Group type: COMPARATOR
Intervention: Objects randomly paired with locations
Number of subjects: 0
Study: 11296072

Group type: EXPERIMENTAL
Intervention: Varicella vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unvaccinated children
Number of subjects: 0
Study: 10215313

Group type: EXPERIMENTAL
Intervention: Alfentanil 10 micrograms kg‐1
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Alfentanil 20 micrograms kg‐1
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Alfentanil 30 micrograms kg‐1
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Alfentanil 40 micrograms kg‐1
Number of subjects: 5

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 5
Study: 7533226

Group type: EXPERIMENTAL
Intervention: Moxonidine 0.2-0.4 mg daily
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 2000
Study: 3280266

Group type: EXPERIMENTAL
Intervention: 750 mg cefuroxime (single intravenous injection)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 750 mg cefuroxime (three doses)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1 g ceftazidime (single intravenous injection)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1 g ceftazidime (three doses)
Number of subjects: 40
Study: 31423576

Group type: COMPARATOR
Intervention: m7-FLIPI risk groups
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: EZH2 mutations
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: EP300 mutations
Number of subjects: 95
Study: 29459361

Group type: EXPERIMENTAL
Intervention: Prasugrel 5 mg
Number of subjects: 1443

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg
Number of subjects: 1443
Study: 27159073

Group type: EXPERIMENTAL
Intervention: Web-based training
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Classroom-based training
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Emergency Medicine (EM) physicians
Number of subjects: 138
Study: 25706751

Group type: EXPERIMENTAL
Intervention: 4000 IU/day of D₃
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 7000 IU/day of D₃
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 60
Study: 24385632

Group type: EXPERIMENTAL
Intervention: Untrained African American participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untrained White participants
Number of subjects: 0
Study: 20518169

Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 60
Study: 19025521

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg once daily for 4 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16522657

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1200 mg b.i.d. the day before surgery and 600 mg b.i.d. after; administered p.o. for 24 h before operation and maintained i.v. for 48 h after operation.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (placebo) administered p.o. for 24 h before operation and maintained i.v. for 48 h after operation.
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) group.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (placebo) group.
Number of subjects: 42
Study: 14653289

Group type: EXPERIMENTAL
Intervention: Listerine Original [AP] (alcohol‐containing essential oil/phenolic compound mouthrinse)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Colgate Chloropharm [AC] (alcohol‐containing chlorhexidine mouthrinse)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Oral B Sensitive [PF] (phosphoric acid containing fluoride mouthrinse)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Distilled water [WC] (control)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Oral B Tooth & Gum Care [AF] (alcohol‐containing fluoride mouthrinse)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Oral B Tooth & Gum Care Alcohol Free [OF] (alcohol free fluoride mouthrinse)
Number of subjects: 54
Study: 11183627

Group type: EXPERIMENTAL
Intervention: Clinicians' attitudes towards recruitment in randomised trials
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Barriers to recruitment
Number of subjects: 20
Study: 8826981

Group type: EXPERIMENTAL
Intervention: Diazoxide treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1590581

Group type: EXPERIMENTAL
Intervention: Micropore filter
Number of subjects: 32

Group type: COMPARATOR
Intervention: No Micropore filter (Control)
Number of subjects: 32
Study: 30924958

Group type: EXPERIMENTAL
Intervention: Family‐based Treatment for ARFID (FBT‐ARFID)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 28
Study: 28861202

Group type: EXPERIMENTAL
Intervention: Arthroscopically guided suprascapular nerve block and blinded axillary nerve block (10 mL 0.25% ropivacaine)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Blinded suprascapular nerve block (10 mL 0.25% ropivacaine)
Number of subjects: 40
Study: 26513517

Group type: EXPERIMENTAL
Intervention: ST + EX (smoking cessation treatment plus exercise intervention)
Number of subjects: 136

Group type: COMPARATOR
Intervention: ST + CTRL (smoking cessation treatment plus wellness education control)
Number of subjects: 136
Study: 25155146

Group type: EXPERIMENTAL
Intervention: Albiglutide 30 mg subcutaneous once weekly
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study: 22733291

Group type: EXPERIMENTAL
Intervention: Canaloplasty with cataract surgery (group K+P)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Canaloplasty alone (group K)
Number of subjects: 63
Study: 20444749

Group type: COMPARATOR
Intervention: Placebo plus methotrexate (group 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg plus placebo (group 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg plus methotrexate (group 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg plus methotrexate (group 4)
Number of subjects: 0
Study: 17383857

Group type: EXPERIMENTAL
Intervention: Lamotrigine (up to 200 mg/day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 16274377

Group type: EXPERIMENTAL
Intervention: Green Prescription physical activity counseling program
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 270
Study: 12087138

Group type: EXPERIMENTAL
Intervention: 30 mg of lansoprazole daily
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 10803269

Group type: EXPERIMENTAL
Intervention: PCR with HPV primers MY09‐MY11
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: PCR using a mixture of two pairs of primers bglobin PG04‐GH20 and HPV MY09‐MY11
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: PCR with human bglobin primers PG04‐GH20
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Overall PCR testing
Number of subjects: 174
Study: 8551824

Group type: COMPARATOR
Intervention: Endoscopic variceal ligation alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Octreotide (50 micrograms intravenous bolus injection followed by intravenous infusion at 50 micrograms per h for 5 days) plus endoscopic variceal ligation
Number of subjects: 100
Study: 2182204

Group type: EXPERIMENTAL
Intervention: Propofol 2 mg.kg‐1/hr with alfentanil infusion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol 3 mg.kg‐1/hr with alfentanil infusion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol 4 mg.kg‐1/hr with alfentanil infusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 7202816

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 20
Study: 31559204

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation (CRT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Concomitant boost radiotherapy (CBRT)
Number of subjects: 40
Study: 28715459

Group type: EXPERIMENTAL
Intervention: Abdominal acupuncture
Number of subjects: 154

Group type: COMPARATOR
Intervention: Sham abdominal acupuncture
Number of subjects: 154
Study: 25581313

Group type: EXPERIMENTAL
Intervention: Enhanced intervention (detailed explanation, written report for physician, follow-up contacts at 2 and 4 months)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Enhanced intervention
Number of subjects: 101

Group type: COMPARATOR
Intervention: Basic/control intervention (informed about diabetes risk factors and blood test result, advised to see a physician)
Number of subjects: 101
Study: 21816963

Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 44
Study: 21791041

Group type: EXPERIMENTAL
Intervention: Structured physical exercise programme (PEP) - instructed to exercise at least five times a week for at least 30 minutes per day
Number of subjects: 102

Group type: COMPARATOR
Intervention: Usual care from the GP
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Structured physical exercise programme (PEP)
Number of subjects: 102
Study: 19453961

Group type: EXPERIMENTAL
Intervention: Gabapentin (600-1,800 mg per day)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 73
Study: 17404825

Group type: EXPERIMENTAL
Intervention: Intensified LDL-C lowering therapy with ezetimibe
Number of subjects: 400

Group type: COMPARATOR
Intervention: HDL-C raising therapy with extended-release niacin
Number of subjects: 400
Study: 14697441

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (Ptx) 400 mg, 3 times daily during radiotherapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (Ptx)
Number of subjects: 40
Study: 11416076

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Herbal medicine
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Homeopathy
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Larger trials published more recently in Medline and in English language
Number of subjects: 207
Study: 9404250

Group type: EXPERIMENTAL
Intervention: Diltiazem 180 mg and trimetazidine 60 mg
Number of subjects: 64
Study: 7683868

Group type: EXPERIMENTAL
Intervention: Chemical splanchnicectomy with alcohol
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo (saline injection)
Number of subjects: 137
Study: 3500642

Group type: EXPERIMENTAL
Intervention: Nabumetone (1,000 mg daily)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Aspirin (3.6 g daily)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 37
Study: 29601981

Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 0
Study: 28088674

Group type: EXPERIMENTAL
Intervention: Web‐based computer intervention targeting substance use and treatment initiation
Number of subjects: 113
Study: 25639980

Group type: EXPERIMENTAL
Intervention: DVD intervention targeting self-efficacy with procedural and sensory information
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard hospital information leaflet (control)
Number of subjects: 83
Study: 23836550

Group type: EXPERIMENTAL
Intervention: Motivation condition (observer is also the recipient of donations)
Number of subjects: 39

Group type: COMPARATOR
Intervention: No motivation condition (observer is just observing)
Number of subjects: 39
Study: 22007015

Group type: EXPERIMENTAL
Intervention: Counseling intervention using the 5 A's model and cognitive‐behavioral techniques
Number of subjects: 1068

Group type: COMPARATOR
Intervention: Information‐attention control condition
Number of subjects: 1068
Study: 18079034

Group type: EXPERIMENTAL
Intervention: core‐build‐up resin
Number of subjects: 216

Group type: COMPARATOR
Intervention: conventional luting cement
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: tribochemical pretreatment of the post
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: dual‐curing bonding system
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: none, dual‐curing bonding, light‐curing bonding (for root dentin pretreatment)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: different regions of the root
Number of subjects: 216
Study: 16782926

Group type: EXPERIMENTAL
Intervention: Very accelerated radiation therapy (62 to 64 Gy in 31 to 32 fractions of 2 Gy over 22 to 23 days)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Conventional radiation therapy (70 Gy in 7 weeks, 35 fractions of 2 Gy over 49 days)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Very accelerated radiation therapy
Number of subjects: 268

Group type: COMPARATOR
Intervention: Conventional radiation therapy
Number of subjects: 268
Study: 12511310

Group type: EXPERIMENTAL
Intervention: Intramuscular dexamethasone (0.6 mg/kg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Oral dexamethasone (0.6 mg/kg)
Number of subjects: 96
Study: 10994801

Group type: EXPERIMENTAL
Intervention: Cerebral MRI in solvent-exposed workers
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cerebral MRI in referents with no former solvent exposure
Number of subjects: 36
Study: 9062855

Group type: EXPERIMENTAL
Intervention: Biodegradable barriers (Polyglactin 910)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-resorbable barriers (ePTFE)
Number of subjects: 20
Study: 8445359

Group type: EXPERIMENTAL
Intervention: Upper cervical adjustments (C2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower cervical adjustments (C7)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Upper cervical sham manipulation
Number of subjects: 0
Study: 3526208

Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 47

Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 47
Study: 30550987

Group type: EXPERIMENTAL
Intervention: Static illustrations with music/sounds
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Static illustrations without music/sounds
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Animated illustrations with music/sounds
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Animated illustrations without music/sounds
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (no enhancements)
Number of subjects: 99
Study: 27943260

Group type: EXPERIMENTAL
Intervention: Individualized, one‐on‐one safe‐transportation program delivered by a registered occupational therapist in two sessions held approximately 1 month apart
Number of subjects: 380

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Individualized safe‐transportation program
Number of subjects: 380
Study: 24917487

Group type: EXPERIMENTAL
Intervention: Housing First intervention (HF)
Number of subjects: 2148

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 2148

Group type: EXPERIMENTAL
Intervention: Substance dependence
Number of subjects: 2148
Study: 23218851

Group type: EXPERIMENTAL
Intervention: Telephone contact from a personal assistant providing contraception education, facilitation of insurance coverage, appointment scheduling, and assistance with childcare and transportation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine follow up
Number of subjects: 50
Study: 21353749

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine (7.7±3.9 mg per day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (untreated, healthy volunteers)
Number of subjects: 30
Study: 19592624

Group type: EXPERIMENTAL
Intervention: Low amount/moderate intensity exercise training
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Low amount/vigorous intensity exercise training
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: High amount/vigorous intensity exercise training
Number of subjects: 387

Group type: COMPARATOR
Intervention: Inactive control group
Number of subjects: 387
Study: 17615797

Group type: EXPERIMENTAL
Intervention: NM-702
Number of subjects: 386

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 386
Study: 15333605

Group type: EXPERIMENTAL
Intervention: 2 mg/2 ml antide (n=30)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 1 mg/ml antide (n=30)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 0.5 mg/ml antide (n=31)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 0.5 mg/0.5 ml antide (n=23)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 0.25 mg/ml antide (n=30)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 0.5 mg/ml antide (considered minimal effective dose)
Number of subjects: 144
Study: 11214722

Group type: EXPERIMENTAL
Intervention: Oleic-acid-enriched diet
Number of subjects: 8

Group type: COMPARATOR
Intervention: Linoleic-acid-enriched diet
Number of subjects: 8